Our data showing significantly elevated CCL5 level in CMD-affected muscles, suggest that CCL5 could be a novel therapeutic target for CMD and that its inhibition could attenuate CMD-associated inflammation and fibrosis. The gene discussed is CCL5; the disease is congenital muscular dystrophy.